Blueprint Medicines Corp (NAS:BPMC)
$ 102.81 0.42 (0.41%) Market Cap: 6.44 Bil Enterprise Value: 6.09 Bil PE Ratio: 0 PB Ratio: 20.73 GF Score: 72/100

Blueprint Medicines Corp AYVAKIT™ FDA Approval Conference Call Transcript

Jan 09, 2020 / 09:30PM GMT
Release Date Price: $80.82 (+0.65%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines AYVAKIT FDA Approval Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Kristin Hodous of Blueprint Medicines. Please go ahead.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good afternoon, everyone. This is Kristin Hodous of Blueprint Medicines, and welcome to our conference call to discuss the FDA approval of AYVAKIT. You can access our press release announcing the approval as well as the slides we'll be reviewing today by going to the investors & media section of our website at www.blueprintmedicines.com. With me on the call today are Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; and Christina Rossi, our Chief Commercial Officer.

Before we get started,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot